ArticleCancer medicine2025
Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPatients with lung cancer tend to have a high incidence of arterial thromboembolism (ATE). However, although ATE is a life-threatening disease, there are insufficient studies evaluating patient characteristics associated with a high risk of ATE in patients with lung cancer. This study aimed to examine the incidence of ATE in Japanese patients with lung cancer and evaluate the incidence of ATE by histological types and treatment patterns to identify high-risk groups.
methodsWe conducted a retrospective cohort study using the National Health Insurance (NHI), Employees' Health Insurance (EHI), and Later-Stage Elderly Healthcare System (LSEHS) claims databases from April 1, 2014, to March 31, 2022. The patients were followed up for up to 5 years after lung cancer diagnosis. The cumulative incidence rates of ATE were calculated, and the histological subtype and treatment pattern were analyzed using the Cox proportional hazards model.
resultsAmong 6340 patients in EHI, 10,857 patients in NHI, and 13,039 patients in LSEHS, patient characteristics such as the median age and the prevalence of comorbidities were different among the three databases. The cumulative incidence rates at 1 year were 1.7%, 4.5%, and 7.2%, and those at 5 years were 3.5%, 8.0%, and 15.9%. The adjusted hazard ratio for small cell lung cancer compared to non-small cell lung cancer was 2.84 (95% confidence interval (CI): 1.46-5.54) in EHI, 0.93 (95% CI: 0.65-1.32) in NHI, and 1.11 (95% CI: 0.85-1.46) in LSEHS. The risk of ATE of RT + systemic therapy and systemic therapy only was higher than surgery only, with a statistically significant difference in the three databases.
conclusionIn any database, the cumulative incidence of ATE increased over the 5 year observation period. Patients who received RT + systemic therapy and those who received systemic therapy only had a higher risk of ATE than those who underwent surgery only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.